CING - Cingulate pops ~76% after hours on trial results for its ADHD treatment drug
- Cingulate ( NASDAQ: CING ) on Thursday reported what it deemed to be positive results from a study assessing its tablet formulation of dexmethylphenidate.
- Shares of the biopharmaceutical company soared more than 75% to $1.92 after hours.
- Dexmethylphenidate is a compound approved by the U.S. Food and Drug Administration for the treatment of attention deficit/hyperactivity disorder (ADHD).
- CING's lead drug candidate CTx-1301 in an investigational, extended-release tablet formulation of dexmethylphenidate.
- "The trial demonstrated that CTx-1301 can be taken with or without food. Multiple pharmacokinetic ( PK ) measurements were taken and adverse events were consistent with previous findings and indicate a favorable tolerability profile," CING said in a statement .
- CING last month said it had started a late-stage trial for CTx-1301, with results expected in Q3 2023.
For further details see:
Cingulate pops ~76% after hours on trial results for its ADHD treatment drug